MDGL MADRIGAL PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1157601 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY92.8%
TTM net income YoY46.2%
TTM EPS YoY24.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-10.7%
Net margin-10.9%
FCF margin-11.8%
EBITDA margin-10.6%
Returns
ROE-24.8%
ROA-11.1%
ROIC (approx.)-21.6%
Asset turnover1.02x
Leverage & solvency
Liabilities / assets56.3%
Debt / equity0.54x
Current ratio3.05x
Interest coverage-4.75x
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio0.1%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $431.27M | $364.25M | $311.34M | $321.08M | $287.27M | $212.80M | $137.25M | $103.32M |
| Cost of revenue | — | — | — | — | — | — | $4.51M | — |
| Gross profit | — | — | — | — | — | — | $132.74M | — |
| R&D expense | $71.75M | $91.18M | $108.69M | $116.27M | $174.00M | $54.08M | $44.17M | $25.65M |
| SG&A expense | $265.71M | $289.38M | $268.52M | $239.98M | $209.12M | $196.86M | $167.88M | $141.22M |
| Operating income | $55.99M | -$56.31M | -$92.72M | -$59.61M | -$113.97M | -$47.20M | -$79.31M | -$67.00M |
| Interest expense | $8.07M | $7.94M | $7.82M | $8.30M | $7.45M | $3.26M | $3.30M | $3.50M |
| Net income | $55.44M | -$57.94M | -$94.39M | -$58.58M | -$114.19M | -$42.28M | -$73.24M | -$59.42M |
| EBITDA | $56.38M | -$55.93M | -$92.34M | -$59.22M | -$113.62M | -$46.83M | -$78.93M | -$66.63M |
| EPS (basic) | 1.90 | -1.99 | -3.25 | — | -4.01 | -1.50 | -2.61 | — |
| EPS (diluted) | 1.83 | -1.99 | -3.25 | — | -4.01 | -1.50 | -2.61 | — |
| Weighted avg. shares (diluted) | 30.31M | 29.15M | 29.03M | — | 28.51M | 28.23M | 28.09M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $514.64M | $292.73M | $227.03M | $198.69M | $300.69M | $191.19M | $188.65M | $105.02M |
| Short-term investments | $446.32M | $546.03M | $585.74M | $784.87M | $814.05M | $610.83M | $659.42M | $826.23M |
| Receivables | $227.38M | $192.31M | $187.36M | $134.48M | $113.28M | $79.23M | $61.43M | $53.82M |
| Inventory | $122.59M | $99.39M | $112.07M | $74.84M | $69.32M | $63.50M | $55.24M | $34.07M |
| Current assets | $1.39B | $1.20B | $1.18B | $1.25B | $1.35B | $1.00B | $987.98M | $1.03B |
| PP&E, net | $13.96M | $11.59M | $8.04M | $1.50M | $2.91M | $1.61M | $1.90M | $2.19M |
| Intangibles | $7.09M | $7.19M | $7.28M | $7.38M | $7.48M | $4.55M | $4.64M | $4.73M |
| Total assets | $1.43B | $1.24B | $1.23B | $1.26B | $1.36B | $1.02B | $996.63M | $1.04B |
| Current liabilities | $454.24M | $374.20M | $338.26M | $310.29M | $391.41M | $196.50M | $167.24M | $169.28M |
| Long-term debt | $341.27M | $340.79M | $340.33M | $339.88M | $339.75M | $118.38M | $118.00M | $117.57M |
| Total debt | $341.27M | $340.79M | $340.33M | $339.88M | $339.75M | $118.38M | $118.00M | $117.57M |
| Total liabilities | $807.45M | $720.92M | $683.87M | $656.90M | $736.73M | $319.40M | $285.99M | $287.86M |
| Shareholders' equity | $626.94M | $523.72M | $543.45M | $602.69M | $625.73M | $695.98M | $710.64M | $754.38M |
| Net debt | -$173.37M | $48.07M | $113.30M | $141.19M | $39.06M | -$72.82M | -$70.64M | $12.55M |
| Shares outstanding | 23.22M | 23.09M | 23.04M | 22.84M | 22.70M | 22.22M | 22.19M | 22.00M |
| Cash flow statement | ||||||||
| Operating cash flow | $120.56M | $23.33M | -$167.44M | -$133.46M | $79.85M | -$47.05M | -$88.89M | -$104.49M |
| Capital expenditure | $3.93M | $4.25M | $3.85M | -$390,000 | $857,000 | $0 | $0 | $195,000 |
| Free cash flow | $116.63M | $19.08M | -$171.28M | -$133.07M | $78.99M | -$47.05M | -$88.89M | -$104.68M |
| Investing cash flow | $93.79M | $34.20M | $192.19M | $27.58M | -$207.00M | $47.86M | $163.88M | -$47.95M |
| Financing cash flow | $9.96M | $3.11M | $2.33M | $8.96M | $236.65M | $1.74M | $8.64M | $19.77M |
| Depreciation & amortization | $391,000 | $381,000 | $386,000 | $392,000 | $358,000 | $377,000 | $379,000 | $363,000 |
| Stock-based compensation | $38.95M | $35.37M | $34.02M | $25.79M | $26.25M | $25.16M | $20.93M | $17.68M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.